Hypercholesterolemia - Pipeline Review, H2 2019

Hypercholesterolemia - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypercholesterolemia - Pipeline Review, H2 2019, provides an overview of the Hypercholesterolemia (Metabolic Disorders) pipeline landscape.

Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. This leads in formation of sticky deposits (called plaque) along the artery walls. Plaque can completely block blood flow through an artery, causing heart attack or stroke. Two forms of the condition exist heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). Risk factors include obese, family history, high blood pressure, smoking and diabetes. Treatment includes statins, bile acid sequestrants, fibric acid derivatives and cholesterol absorption inhibitors

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypercholesterolemia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 7, 14, 9, 2, 16, 6 and 4 respectively. Similarly, the Universities portfolio in Phase 0, Preclinical and Discovery stages comprises 1, 7 and 1 molecules, respectively.

Hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypercholesterolemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypercholesterolemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hypercholesterolemia - Overview
Hypercholesterolemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hypercholesterolemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypercholesterolemia - Companies Involved in Therapeutics Development
3SBio Inc
AbbVie Inc
AD Pharmaceuticals Co Ltd
AFFiRiS AG
Akcea Therapeutics Inc
Amryt Pharma Plc
Arrowhead Pharmaceuticals Inc
AstraZeneca Plc
Beijing Mabworks Biotech Co Ltd
BioLingus AG
CardioPharma Inc
Centeer BioTherapeutics Ltd Co
Chong Kun Dang Pharmaceutical Corp
Civi Biopharma Inc
Cumberland Pharmaceuticals Inc
CymaBay Therapeutics Inc
Daewoong Co Ltd
Delivra Corp
Dogma Therapeutics Inc
Draupnir Bio Aps
Esperion Therapeutics Inc
Gemphire Therapeutics Inc
Golden Biotechnology Corp
Hingez Therapeutics Inc
Innovent Biologics Inc
Jiangsu Hengrui Medicine Co Ltd
Kadmon Corp LLC
Kyorin Pharmaceutical Co Ltd
LIB Therapeutics LLC
Lipigon Pharmaceuticals AB
LipimetiX Development Inc
Luye Pharma Group Ltd
Madrigal Pharmaceuticals Inc
Medlab Clinical Ltd
Novo Nordisk AS
Nyrada Inc
OliPass Corporation
Pfizer Inc
Portola Pharmaceuticals Inc
Precision Biosciences Inc
Progenra Inc
Regeneron Pharmaceuticals Inc
RegenxBio Inc
Repair Biotechnologies Inc
Shanghai Junshi Bioscience Co Ltd
Shenzhen HighTide Biopharmaceutical Ltd
Shifa Biomedical Corp
The Medicines Company
Viking Therapeutics Inc
Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Teruisi Pharmaceutical Inc
Hypercholesterolemia - Drug Profiles
Hypercholesterolemia - Dormant Projects
Hypercholesterolemia - Discontinued Products
Hypercholesterolemia - Product Development Milestones
Appendix